Hongkong Winhealth Pharma Group (Winhealth Pharma) and Taiwan TWi Biotechnology, Inc. (TWiB) announced strategic partnership granting Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases. The prevalence of EB in the United States is about 10.65 per million, equivalent to an estimated 15,000 patients in China. Hereditary epidermolysis bullosa (EB) is a group of rare hereditary skin diseases. Due to genetic mutations, the skin becomes very fragile, just like the wings of a butterfly. A slight collision or friction produces blisters or bloody vesicles, which may then cause trauma and ulceration. Other mucosal tissues of the body may also be affected. There is no effective treatment for EB worldwide. EB is listed in the first national list of 121 rare diseases in China. Based on clinical studies conducted, AC-203 alleviates EB symptoms, reducing blister formation and accelerating wound healing, while also demonstrating a good safety profile. AC-203 has been granted Orphan Drug Designation and rare pediatric drug status by FDA.